Psoriatic Arthritis – Pipeline Review, H2 2020

Global Markets Direct’s, ‘Psoriatic Arthritis – Pipeline Review, H2 2020’, provides an overview of the Psoriatic Arthritis pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Psoriatic Arthritis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Psoriatic Arthritis and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

– The report provides a snapshot of the global therapeutic landscape of Psoriatic Arthritis

– The report reviews pipeline therapeutics for Psoriatic Arthritis by companies and universities/research institutes based on information derived from company and industry-specific sources

– The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

– The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

– The report reviews key players involved Psoriatic Arthritis therapeutics and enlists all their major and minor projects

– The report assesses Psoriatic Arthritis therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

– The report summarizes all the dormant and discontinued pipeline projects

– The report reviews latest news related to pipeline therapeutics for Psoriatic Arthritis

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

- Identify and understand important and diverse types of therapeutics under development for Psoriatic Arthritis

- Identify potential new clients or partners in the target demographic

- Develop strategic initiatives by understanding the focus areas of leading companies

- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

- Devise corrective measures for pipeline projects by understanding Psoriatic Arthritis pipeline depth and focus of Indication therapeutics

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies mentioned

3SBio Inc

AbbVie Inc

Aclaris Therapeutics Inc

Affibody AB

Alpine Immune Sciences Inc

AltruBio Inc

Alvotech ehf

Amgen Inc

Avotres Inc

Bio-Thera Solutions Ltd

Biocad

Biocon Ltd

BioXpress Therapeutics SA

Boehringer Ingelheim International GmbH

Bristol-Myers Squibb Co

Celltrion Inc

DM Bio Ltd

DNX Biopharmaceuticals Inc

Eli Lilly and Co

FYB202 GmbH & Co KG

Galapagos NV

GenFleet Therapeutics (Shanghai) Inc

Hengenix Biotech Inc

Huabo Biopharm Co Ltd

Immunwork Inc

Innovent Biologics Inc

Innovimmune Biotherapeutics Inc

InSight Biopharmaceuticals Ltd

Johnson & Johnson

Kangpu Biopharmaceuticals Ltd

Luye Pharma Group Ltd

Mabpharm Ltd

Machavert Pharmaceuticals LLC

Mycenax Biotech Inc

NeuClone Pty Ltd

Nichi-Iko Pharmaceutical Co Ltd

Novartis AG

Pfizer Inc

Pharmapraxis

Polpharma Biologics

Rheos Medicines Inc

RNAx Ltd

Sagacity pharmaceuticals

Shanghai Junshi Bioscience Co Ltd

Siam Bioscience Co Ltd

Sichuan Haisco Pharmaceutical Co Ltd

Sun Pharma Advanced Research Company Ltd

SynAct Pharma AB

UCB SA

XBiotech Inc

Xbrane Biopharma AB

Table of Contents

Table of Contents

Introduction

Psoriatic Arthritis- Overview

Psoriatic Arthritis- Therapeutics Development

Psoriatic Arthritis- Therapeutics Assessment

Psoriatic Arthritis- Companies Involved in Therapeutics Development

Psoriatic Arthritis- Drug Profiles

Psoriatic Arthritis- Dormant Projects

Psoriatic Arthritis- Discontinued Products

Psoriatic Arthritis- Product Development Milestones

Appendix

List of Tables

List of Tables

Number of Products under Development for Psoriatic Arthritis, H2 2020

Number of Products under Development by Companies, H2 2020

Products under Development by Companies, H2 2020

Number of Products by Stage and Target, H2 2020

Number of Products by Stage and Mechanism of Action, H2 2020

Number of Products by Stage and Route of Administration, H2 2020

Number of Products by Stage and Molecule Type, H2 2020

Psoriatic Arthritis – Pipeline by 3SBio Inc, H2 2020

Psoriatic Arthritis – Pipeline by AbbVie Inc, H2 2020

Psoriatic Arthritis – Pipeline by Aclaris Therapeutics Inc, H2 2020

Psoriatic Arthritis – Pipeline by Affibody AB, H2 2020

Psoriatic Arthritis – Pipeline by Alpine Immune Sciences Inc, H2 2020

Psoriatic Arthritis – Pipeline by AltruBio Inc, H2 2020

Psoriatic Arthritis – Pipeline by Alvotech ehf, H2 2020

Psoriatic Arthritis – Pipeline by Amgen Inc, H2 2020

Psoriatic Arthritis – Pipeline by Avotres Inc, H2 2020

Psoriatic Arthritis – Pipeline by Bio-Thera Solutions Ltd, H2 2020

Psoriatic Arthritis – Pipeline by Biocad, H2 2020

Psoriatic Arthritis – Pipeline by Biocon Ltd, H2 2020

Psoriatic Arthritis – Pipeline by BioXpress Therapeutics SA, H2 2020

Psoriatic Arthritis – Pipeline by Boehringer Ingelheim International GmbH, H2 2020

Psoriatic Arthritis – Pipeline by Bristol-Myers Squibb Co, H2 2020

Psoriatic Arthritis – Pipeline by Celltrion Inc, H2 2020

Psoriatic Arthritis – Pipeline by DM Bio Ltd, H2 2020

Psoriatic Arthritis – Pipeline by DNX Biopharmaceuticals Inc, H2 2020

Psoriatic Arthritis – Pipeline by Eli Lilly and Co, H2 2020

Psoriatic Arthritis – Pipeline by FYB202 GmbH & Co KG, H2 2020

Psoriatic Arthritis – Dormant Projects, H2 2020

Psoriatic Arthritis – Discontinued Products, H2 2020

List of Figures

List of Figures

Number of Products under Development for Psoriatic Arthritis, H2 2020

Number of Products under Development by Companies, H2 2020

Number of Products by Top 10 Targets, H2 2020

Number of Products by Stage and Top 10 Targets, H2 2020

Number of Products by Top 10 Mechanism of Actions, H2 2020

Number of Products by Stage and Top 10 Mechanism of Actions, H2 2020

Number of Products by Top 10 Routes of Administration, H2 2020

Number of Products by Stage and Top 10 Routes of Administration, H2 2020

Number of Products by Top 10 Molecule Types, H2 2020

Number of Products by Stage and Top 10 Molecule Types, H2 2020

    Pricing

Discounts available for multiple purchases.

reportstore@globalmarketsdirect.com
+44 20 7947 2745

Saved reports